{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116047","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.129579+00:00","generated_at":"2026-06-08T07:02:52.331100+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elutia closes Orthobiologics divestiture for up to $35M in cash proceeds","bullets":["Upfront payment of $15M due Nov 17, 2023, plus up to $20M earnout over 5 years.","Combined with Sept 2023 private placement, total potential cash exceeds $60M.","Company refocuses on drug-eluting biomatrix platform, including CanGaroo RM.","Transaction closed Nov 8; buyer is Berkeley Biologics (GNI Group subsidiary).","Mizuho Securities acted as financial advisor; Kilpatrick Townsend as legal advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116047","json":"https://secwatch.observer/filing/0001104659-23-116047.json","markdown":"https://secwatch.observer/filing/0001104659-23-116047.md","text":"https://secwatch.observer/filing/0001104659-23-116047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923116047/0001104659-23-116047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923116047/tm2330025d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:02:52.331100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}